1. Home
  2. LTBR vs ACIU Comparison

LTBR vs ACIU Comparison

Compare LTBR & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LTBR

Lightbridge Corporation

N/A

Current Price

$4.37

Market Cap

191.7M

ML Signal

N/A

Logo AC Immune SA

ACIU

AC Immune SA

N/A

Current Price

$2.36

Market Cap

229.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LTBR
ACIU
Founded
1992
2003
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
191.7M
229.7M
IPO Year
2015
2015

Fundamental Metrics

Financial Performance
Metric
LTBR
ACIU
Price
$4.37
$2.36
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $8.60
AVG Volume (30 Days)
★ 728.3K
193.5K
Earning Date
11-02-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
★ 0.62
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$422.39
Revenue Next Year
N/A
$377.85
P/E Ratio
$6.77
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.91
$2.02
52 Week High
$20.85
$3.90

Technical Indicators

Market Signals
Indicator
LTBR
ACIU
Relative Strength Index (RSI) 36.82 50.40
Support Level N/A $2.09
Resistance Level $5.61 $2.47
Average True Range (ATR) 0.35 0.17
MACD -0.04 0.01
Stochastic Oscillator 31.86 72.28

Price Performance

Historical Comparison
LTBR
ACIU

About LTBR Lightbridge Corporation

Lightbridge Corp is a United States-based nuclear fuel technology company. The business activity of the firm is functioned through one business segment, engaged in research and development and commercialization of its nuclear fuel. The Nuclear Fuel Technology segment develops next generation nuclear fuel technology that increases the power output of commercial reactors and reduces the cost of generating electricity. Geographically, its operations are functioned through the region of Unites States.

About ACIU AC Immune SA

AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: